Direct cost savings as well as indirect effects created by increased diagnostics accuracy.
The unique combination of molecular biology, robotics, NGS and AI provides market-leading accuracy.
Manual stages of work almost fully minimized, enabling unparallelled scalability and processing times.
Geno1® is a pre-sequencing technology that combines molecular biology, robotics, next-generation DNA sequencing (NGS) and artificial intelligence (AI).
Geno1® addresses the key shortcomings of NGS-based solutions through its minimalistic but powerful design, leading to substantially lower test costs, higher test accuracy and faster turn-around-time. Geno1® is also massively scalable technology in terms of number of samples and targets.
Geno1® unlocks the use of NGS in an unprecedented way and democratises the precision diagnostics.
Our unique ligation-based molecular barcoding Geno1 technology maximizes the power of NGS platforms and AI. The laboratory design of Geno1® has been guided by the principle of minimalism: reduce all processing steps to minimum and make them as simple as possible. Through these design choices, Geno1® provides a lightweight but powerful molecular counting platform which scales to any number of relevant targets within any number of patient samples.
We offer Geno1® for out-licensing and are continuously looking for new long-term partnerships both within oncology and other verticals.
Join our journey to make an impact.